Price movement over the last 24 hours
Alexandria Real Estate Equities Inc vs Novavax Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $47.74 (market cap $8.34B), while Novavax Inc trades at $9.27 (market cap $1.53B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 5.5× Novavax Inc's market cap, and Alexandria Real Estate Equities Inc pays a 6.02% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ARE | NVAX | |
|---|---|---|
Market Cap | $8.34B | $1.53B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $11.19 |
52-Week Low | $40.41 | $6.22 |
Enterprise Value | $20.80B | $1.04B |
Dividend Yield | 6.02% | — |
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $47.88, down 1.3% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a high P/E of 102.99 and negative net income margin of -37.09%, though it maintains a strong gross margin of 67.76% and positive operating cash flow. Recent news highlights corporate responsibility initiatives and a declared dividend of $0.72 per share for Q2 2026.
The outlook is cautious due to profitability challenges and elevated debt, but analyst consensus suggests moderate upside to a $51.00 price target. Key risks include sustained negative earnings and interest rate sensitivity, while institutional sentiment leans neutral with 58.33% hold ratings.
Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.
The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.
Trailing returns across standard periods
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →